# vectormune<sup>®</sup> FP-MG+AE

- Mycoplasma gallisepticum
- Fowl Pox
- Avian Encephalomyelitis

## **APPROVED SPECIES**

Chickens

### **VACCINE TYPE**

 Live FP-vectored MG vaccine in combination with classic live AE virus

#### **VACCINE CONSTRUCT**

- Vector: Live Fowl Pox
- Contains one insert of the field R MG strain and one insert of the S6 MG strain
- Live Avian Encephalomyelitis virus

#### **DISEASE PROTECTION**

- Mycoplasma gallisepticum
- Fowl Pox
- Avian Encephalomyelitis

#### **VACCINE PRESENTATION**

Freeze-dried

## ROUTE OF ADMINISTRATION

• Wing-web

## AGE OF ADMINISTRATION

8-week-old chickens

#### PACKAGING (PRODUCT CODE)

• 10 x 1,000 doses (B431H1US)

## QUALITY

 Thoroughly tested for purity, sterility, potency, and safety, and compliant with all applicable USDA and Ceva standards.

## **Key Advantages**

- MG protection without use of a conventional live MG vaccine
- No shedding, spreading of the vaccine strain in the environment, preventing vaccine-induced MG outbreaks
- No reversion to virulence
- Convenient, combining MG, FP, and AE protection in one application
- Compatible with antibiotic medication programs
- Does not produce detectable antibodies, allowing monitoring of field infection
- Provides protection against fowl pox and avian encephalomyelitis equal to conventional FP and AE vaccines



See reverse side and package label for complete use directions and information



## VECTORMUNE<sup>®</sup> FP-MG+AE

AVIAN ENCEPHALOMYELITIS - FOWL POX -MYCOPLASMA GALLISEPTICUM VACCINE Live Virus, Live Fowl Pox Vector

#### **DESCRIPTION**

VECTORMUNE<sup>®</sup> FP MG & AE is a genetically engineered live virus vaccine for the vaccination of chickens as an aid in the prevention of fowl pox and *Mycoplasma gallisepticum*. The vaccine also contains a conventional live virus for vaccination as an aid in the prevention of avian encephalomyelitis. The fowl pox vaccine has been genetically engineered to contain and express key protective *Mycoplasma gallisepticum* bacterial antigens.

#### **INDICATIONS**

Administer by wing web to healthy, susceptible chickens at least eight weeks of age but at least four weeks prior to the start of egg production. Chickens receiving this vaccine must not have been previously vaccinated with a fowl pox vaccine.

#### **DOSAGE AND ADMINISTRATION**

Remove seal and stopper from vaccine vial and diluent vial. Pour entire contents of diluent vial into vaccine vial, insert stopper, and shake well. The vaccine is ready for use and should be used within one hour. Hold each individual bird and spread the wing with the underside facing up. Dip the two-pronged wing web applicator into the vaccine so that the grooves fill with liquid and deliver 0.01 mL per bird. Insert the double-pronged applicator into the web portion of the wing avoiding blood vessels, muscle, and bone. Seven to 10 days after vaccination, observe several chickens for evidence of "takes" that include swelling and/or scab formation at the site of injection.

Chickens receiving this vaccine must not have been previously vaccinated with a fowl pox vaccine.

#### CAUTION

Store vaccine at 35 - 45°F (2 - 7°C). Do not vaccinate within 21 days of slaughter. Use entire contents immediately after rehydrating. Burn containers and all unused contents. Contains gentamicin and amphotericin B as preservatives. Federal regulations prohibit repackaging or sale of the contents of this package in fractional units. Do not accept if seal is broken. All birds in the flock should be vaccinated at one time. For veterinary use only.

#### NOTICE

This vaccine has been thoroughly tested for safety, purity, potency, and sterility and is in compliance with all applicable USDA and Ceva standards.



Manufactured by: Biomune Company

Distributed by: Ceva Animal Health, LLC 8735 Rosehill Road, Ste. 300 Lenexa, KS 66215

Tel: 913-894-0230 www.ceva.us

All trademarks are owned by Ceva Santè Animale S.A. and its affiliates.